Last updated on June 2020

Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Brief description of study

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

Clinical Study Identifier: NCT04186845

Find a site near you

Start Over

Tower Urology

Los Angeles, CA United States
  Connect »

John Wayne Cancer Institute

Santa Monica, CA United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Urology San Antonio

San Antonio, TX United States
  Connect »

Emory Healthcare

Atlanta, GA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.